Advertisement


Mansoor R. Mirza, MD, on Ovarian Cancer: Roundup of ESMO 2019 Top Abstracts

ESMO 2019 Congress

Advertisement

Mansoor R. Mirza, MD, of Copenhagen University Hospital, offers his perspective on three studies presented in the Presidential Symposium: the PRIMA/ENGOT-OV26/ GOG-3012 trial (niraparib for newly diagnosed advanced disease); the PAOLA-1/ENGOT-ov25 trial (olaparib plus bevacizumab maintenance therapy in newly diagnosed advanced disease); and the VELIA/COG-3005 study (integrating veliparib with front-line chemotherapy and maintenance therapy) (Abstracts LBA 1–4).



Related Videos

Lung Cancer
Immunotherapy

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses study findings from the first phase III trial to show PD-1 and CTLA-4 inhibition is effective in non–sm...

Gynecologic Cancers
Immunotherapy

Isabelle Ray-Coquard, MD, PhD, on Ovarian Cancer: Olaparib Plus Bevacizumab

Isabelle Laure Ray-Coquard, MD, PhD, of the Centre Leon Bérard, discusses phase III study findings in patients with newly diagnosed, advanced ovarian cancer who received olap...

Hepatobiliary Cancer

Ghassan K. Abou-Alfa, MD, MBA, on Cholangiocarcinoma: ClarIDHy Trial of Ivosidenib vs Placebo

Ghassan K. Abou-Alfa, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings showing improvement in progression-free survival among patients w...

Skin Cancer
Immunotherapy

Ana Maria Arance Fernandez, MD, PhD, on Advanced Melanoma: Treatment With Cobimetinib/Atezolizumab vs Pembrolizumab

Ana Maria Arance Fernandez, MD, PhD, of the Hospital Clínic de Barcelona, discusses the negative results of the phase III IMspire170 trial, which evaluated cobimetinib/atezol...

Breast Cancer
Immunotherapy

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: KEYNOTE-522 Trial of Pembrolizumab Plus Chemotherapy

Peter Schmid, MD, PhD, of Queen Mary University of London Barts Cancer Institute, discusses pathologic complete response data from a phase III study of pembrolizumab/chemothe...

Advertisement

Advertisement



Advertisement